In a report released today, Mark Breidenbach from Oppenheimer assigned a Hold rating to Bluebird Bio (BLUE). The company’s shares closed last Tuesday at $27.79, close to its 52-week low of $24.24.
According to TipRanks.com, Breidenbach is a 4-star analyst with an average return of 15.3% and a 40.5% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Global Blood Therapeutics, and Iovance Biotherapeutics.
Currently, the analyst consensus on Bluebird Bio is a Moderate Buy with an average price target of $45.36, representing a 64.9% upside. In a report released yesterday, Morgan Stanley also maintained a Hold rating on the stock with a $36.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $72.51 and a one-year low of $24.24. Currently, Bluebird Bio has an average volume of 2.33M.
Based on the recent corporate insider activity of 100 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLUE in relation to earlier this year. Last month, Nick Leschly, the President & CEO of BLUE bought 203,355 shares for a total of $1,118,453.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
